1 completed, 1 unknown, 1 withdrawn. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Alipogene tiparvovec: new trials by email Literature Review of Alipogene tiparvovec trials Research Report on Alipogene tiparvovec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alipogene Tiparvovec for the Treatment of LPLD Patients alipogene tiparvovec, Prednisolone, Cyclosporins - LPL Deficiency | Phase 2 | Withdrawn | UniQure Biopharma B.V. | 2016-10-01 | 2017-08-17 | |
| Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects Alipogene Tiparvovec (AMT-011), Human LPL [S447X], mycophenolate mofetil, cyclosporine - Familial Lipoprotein Lipase Deficiency | Phase 2 / Phase 3 | Completed | Amsterdam Molecular Therapeutics | 5 | 2009-02-01 | 2011-09-29 |
| Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X] Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Mycophenolate mofetil, cyclosporine - Familial Lipoprotein Lipase Deficiency | Phase 2 / Phase 3 | Unknown | Amsterdam Molecular Therapeutics | 14 | 2007-08-01 | 2011-09-30 |
Hyperlipoproteinemia Type I (3)
Amsterdam Molecular Therapeutics (2) · UniQure Biopharma B.V. (1)
Canada (3) · United States (1)